Compare Paycom Software Inc (PAYC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs Sanofi SA — how do they compare? Paycom Software Inc trades at $232.22 (market cap $10.36B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 9.2× Paycom Software Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Paycom Software Inc for 84 Days and Sanofi SA for 94 Days on average.
| PAYC | SNY | |
|---|---|---|
Market Cap | $10.36B | $95.18B |
Volume | 666,294 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $240.52 | $52.34 |
52-Week Low | $113.59 | $39.51 |
Typical Hold Time | 84 Days | 94 Days |
Enterprise Value | $11.15B | $114.48B |
Dividend Yield | 0.65% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $229.90, up 2.83% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company reported robust Q2 2026 results with 10% revenue growth and raised full-year guidance, supported by a high gross profit margin of 83.67% and solid cash flow generation. Analyst sentiment is mixed but leans positive, with a consensus price target of $207.75.
The outlook remains favorable due to operational leverage and product innovation, though risks include competitive pressures and market volatility. Upside potential hinges on sustained earnings growth and institutional confidence, while any guidance miss or macroeconomic slowdown could pressure the stock.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
